Literature DB >> 15671258

Predictors of lung cancer among asbestos-exposed men in the {beta}-carotene and retinol efficacy trial.

Mark R Cullen1, Matt J Barnett, John R Balmes, Brenda Cartmel, Carrie A Redlich, Carl A Brodkin, Scott Barnhart, Linda Rosenstock, Gary E Goodman, Sam P Hammar, Mark D Thornquist, Gilbert S Omenn.   

Abstract

Despite numerous published studies, debate continues regarding the risk of developing lung cancer among men exposed occupationally to asbestos, particularly those without radiographic or functional evidence of asbestosis. The beta-Carotene and Retinol Efficacy Trial (CARET), a study of vitamin supplementation for chemoprevention of lung cancer, has followed 4,060 heavily exposed US men for 9-17 years. Lung cancer incidence for 1989-2002 was analyzed using a stratified proportional hazards model. The study confirmed excessive rates of lung cancer among men with radiographic asbestosis. Comparison of study arms revealed a strong, unanticipated synergy between radiographic profusion category and the active intervention. In the large subgroup of men with normal lung parenchyma on chest radiograph at baseline, there was evidence of exposure-related lung cancer risk: Men with more than 40 years' exposure in high-risk trades had a risk approximately fivefold higher than men with 5-10 years, after adjustment for covariates. The effect in these men was independent of study intervention arm, but pleural plaques on the baseline radiograph and abnormal baseline flow rate were strong independent predictors of subsequent lung cancer. Residual confounding by subclinical asbestosis, exposure to unmeasured lung carcinogens, or differences in smoking are unlikely to explain these observations better than a carcinogenic effect of asbestos per se.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671258     DOI: 10.1093/aje/kwi034

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

Review 1.  Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.

Authors:  Clementina Mesaros; Andrew J Worth; Nathaniel W Snyder; Melpo Christofidou-Solomidou; Anil Vachani; Steven M Albelda; Ian A Blair
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

2.  Drugs for preventing lung cancer in healthy people.

Authors:  Marcela Cortés-Jofré; José-Ramón Rueda; Claudia Asenjo-Lobos; Eva Madrid; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2020-03-04

3.  Genome-wide Gene-Asbestos Exposure Interaction Association Study Identifies a Common Susceptibility Variant on 22q13.31 Associated with Lung Cancer Risk.

Authors:  Chen-Yu Liu; Isabelle Stücker; Chu Chen; Gary Goodman; Michelle K McHugh; Anthony M D'Amelio; Carol J Etzel; Su Li; Xihong Lin; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-21       Impact factor: 4.254

4.  Chrysotile effects on the expression of anti-oncogene P53 and P16 and oncogene C-jun and C-fos in Wistar rats' lung tissues.

Authors:  Yan Cui; Yuchan Wang; Jianjun Deng; Gongli Hu; Faqin Dong; Qingbi Zhang
Journal:  Environ Sci Pollut Res Int       Date:  2017-09-13       Impact factor: 4.223

Review 5.  Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

Authors:  Goran Bjelakovic; Dimitrinka Nikolova; Lise Lotte Gluud; Rosa G Simonetti; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

Review 6.  Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.

Authors:  Luigina Micolucci; Most Mauluda Akhtar; Fabiola Olivieri; Maria Rita Rippo; Antonio Domenico Procopio
Journal:  Oncotarget       Date:  2016-09-06

Review 7.  Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk.

Authors:  John S Fry; Jan S Hamling; Peter N Lee
Journal:  BMC Cancer       Date:  2012-10-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.